Published in Gene Therapy Weekly, August 16th, 2001
In previous and current human trials, endostatin therapy has been administered via daily injections and infusion pumps. "Difficulties with the stability, manufacture, and long-term administration of recombinant anti-angiogenic proteins have prompted investigators to use gene therapy to generate these proteins in vivo," explained Andrew L. Feldman and colleagues,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.